A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

Summary

The study is a double-blind, placebo-controlled, random-order, single-dose crossover trial of sildenafil 50 \& 100 mg added to stable antipsychotic treatment in schizophrenia patients to assess whether this PDE5 inhibitor improves cognitive functioning (including verbal memory, fluency, attention, spatial memory, motor speed, and executive function) and clinical symptoms (psychotic, negative, mood symptoms, and self-reports of side-effects).

Timeline

Start

2006-02

Primary completion

2007-09

Completion

2008-09

Outcome

Missed primary endpoint

paper Neither dose of sildenafil significantly affected cognitive performance or symptom ratings compared to the placebo. PMID 18716761 ↗

Publications

• Results Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl). 2009 Jan;202(1-3):411-7. doi: 10.1007/s00213-008-1278-5. Epub 2008 Aug 21.

Drugs

Indications